Insulet Corporation (PODD) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposa...
Insulet Corporation's revenue increased 30.7% year over year, from $2.07B to $2.71B.
Net income decreased 40.9% over the same period, from $418.3M to $247.1M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 638% in total.
Total debt decreased by 28.2% to $930.8M.
The debt-to-equity ratio stands at 0.61, indicating a moderate leverage profile.
Operating cash flow grew 32.3% to $569.3M.
Insulet Corporation maintains a moderate net profit margin of 9.1%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $1.19B+57.3% | $103.0M | $798.7M | $113.6M | $100.5M | $2.47B | $1.37B | $607.5M |
| Q1 FY2024 | $441.7M-62.8% | $51.5M | $306.8M | $56.9M | $87.6M | $2.62B | $1.36B | $790.7M |
| Q2 FY2024 | $930.2M+110.6% | $240.1M | $637.7M | $111.5M | $184.1M | $2.88B | $1.36B | $998.4M |
| Q3 FY2024 | $1.47B+58.5% | $317.6M | $1.01B | $199.6M | $282.6M | $3.03B | $1.36B | $1.12B |
| Q1 FY2025 | $569.0M-61.4% | $35.4M | $409.0M | $88.8M | $63.8M | $3.52B | $1.61B | $1.33B |
| Q2 FY2025 | $1.22B+114.1% | $57.9M | $861.3M | $209.9M | $260.3M | $3.47B | $939.0M | $1.46B |
| Q3 FY2025 | $1.92B+58.0% | $145.5M | $1.37B | $327.5M | $386.0M | $3.03B | $934.9M | $1.38B |
| Q1 FY2026 | $761.7M-60.4% | $91.1M | $529.1M | $122.1M | $113.8M | $2.99B | $929.5M | $1.30B |
Balance Sheet Summary (Latest Period)
Total Assets
$3.19B
Total Liabilities
$1.68B
Total Equity
$1.52B
Cash & Equivalents
N/A
Total Debt
$930.8M
Current Assets
$1.91B
Current Liabilities
$680.1M
Retained Earnings
$287.4M